Sub-threshold TMS (T-PEMF) -
Electrode-Free Brain Stimulation
Clinic‑grade TMS outcomes. At home.
The only EU MDR certified home neurostimulation with proven efficacy in TRD - even after ECT failure.
Clinic-grade TMS outcomes at home
EU MDR certified sub-threshold TMS (T-PEMF) with sham-controlled remission in TRD.
~70%
Remission at 8 weeks in a dose-response RCT in TRD (Straasø 2014)
34% / 61% / NNT 3.4
Sham-controlled remission / response / number needed to treat for remission at 5 weeks in TRD (Martiny 2010)
29%
Remission in ECT non-responders (Larsen 2020)
20,000+
Sessions in 10+ years. Zero serious adverse events
Depression
Key results in treatment resistant depression:
~70% remission at 8 weeks in dose-response RCT
34% remission / 61% response (sham-controlled)
29% remission in ECT non-responders
50% decrease in patients reporting side effects from concurrent medication - 75% among remitters
85% treatment compliance across studies
0 serious adverse events across 20,000+ sessions
Parkinson's Disease
Key results in Parkinson’s:
Improved mobility and ADL scores (PDQ-39)
19% improvement in sit-to-stand speed at 26 weeks
CSF erythropoietin elevation (p=0.012)
98% treatment compliance over 26 weeks
12-month sham-controlled RCT ongoing
Functional and biomarker findings supports the neurobiological effects of sub-threshold TMS (T-PEMF) in patients with Parkinson's Disease.
Why sit-to-stand matters in Parkinson's
First evidence of a neurobiological activation
Ongoing: 12-Month sham-controlled RCT in Parkinson's
Peer-reviewed clinical evidence
Backed by science
6+
Peer-reviewed clinical publications - including sham-controlled RCTs, dose-response studies, independent multicenter trials, and real-world outcomes data
34% / 61%
Sham-controlled remission / response in strictly defined TRD (≥2 failed antidepressant courses) in a 5-week treatment protocol, n=50 (Martiny 2010)
~70%
Remission in an 8-week treatment protocol in a dose-response RCT in TRD, n=58 (Straasø 2014)
Zero
Serious Adverse Events in 20,000+ sessions (CER)
29%
Remission in patients who did not respond to ECT, n=19 (Larsen 2020)
100%
Remission in relapsed remitters at 2-year follow-up, n=13 (Bech 2015)
Clinically differentiated by design
Unique patented technology, engineered for efficacy and safety, validated through trials, and positioned against established treatment benchmarks.
ECT Non-Responder Efficacy
29% remission in patients who failed ECT, n=19 (Larsen 2020) - the only home neurostimulation with published efficacy in this hardest-to-treat population.
85-98% Compliance
Consistently high compliance rates across all studies. No electrode placement complexity, no scalp tingling, imperceptible treatment.
Sustained Effect
2-year follow-up shows 55% sustained remission. 100% of relapsed patients, n=13, achieved remission again with re-treatment (Bech 2015).
Sub-threshold TMS was originally named Transcranial Pulsed Electromagnetic Fields (T-PEMF), a form of transcranial magnetic stimulation that operates at field intensities significantly lower than conventional in-clinic TMS.
This difference changes everything. At sub-threshold intensities, there's no scalp pain, no muscle twitching and no clinic visits for stimulation. Patients stimulate at home, 30 minutes daily. The stimulation is imperceptible, profoundly strengthening the sham-controlled trial data - effectively adressing the well-established challenge of adequate blinding in other brain stimulation devices.
The technology was developed at leading Danish research institutions and university hospitals, tested in independent clinical trials, and is now in routine use across Danish public psychiatry.
Re5® Technology
The five-phase regeneration mechanism
Sub-threshold transcranial magnetic stimulation (T-PEMF) delivered through a structured sequence of biological activation and recovery.
1
Application
A 7-coil electromagnetic headset applied over the scalp. No electrode contact. 30-minute daily sessions at home.
2
Induce
Pulsed electromagnetic fields (50 Hz, 3 ms pulses) induce electric fields (E-fields) in brain tissue - sub-threshold and imperceptible.
3
Activate
E-fields activate intracellular processes, triggering release of neurotransmitters and growth factors that enhance neuroplasticity.
4
Acceleration
Activated cells release signaling molecules to neighboring cells, accelerating biochemical processes throughout neural networks.
5
Regenerates
Cellular structures regenerates over 5-8 weeks - improved neural connectivity, blood flow, and functional recovery measured clinically.
Born at leading Danish research institutions and validated through independent multicenter trials, Re5 has been adopted into routine psychiatric practice within university hospitals, with renewed public-sector contracts reflecting institutional trust in its clinical performance and safety.
References
no.
reference
link
